AU Stock MarketDetailed Quotes
IMC Immuron Ltd
- 0.084
- -0.001-1.18%
20min DelayMarket Closed Jun 20 15:32 AET
19.14MMarket Cap-4941P/E (Static)
0.085High0.084Low207.81KVolume0.085Open0.085Pre Close17.66KTurnover0.17052wk High0.11%Turnover Ratio227.80MShares0.06552wk Low-0.017EPS TTM15.84MFloat Cap673.436Historical HighLossP/E (Static)188.57MShs Float0.050Historical Low-0.017EPS LYR1.18%Amplitude--Dividend TTM1.09P/B1Lot Size--Div YieldTTM
About Immuron Ltd Company
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Company Profile
SymbolIMC
Company NameImmuron Ltd
Founded1994
MarketASX
Employees6
Fiscal Year Ends06-30
AddressChapman Street Unit 10, 25-37
CityMelbourne
CountryAustralia
Zip Code3130
Phone+61 398245254
Websitehttps://www.immuron.com.au
Company Executives
- Name
- Position
- Salary
- Steven Lydeamore
- Chief Executive Officer
- 580.57K
- Dr. Jerry Kanellos, PhD
- Chief Operating Officer
- 313.09K
- Phillip A. Hains
- Chief Financial Officer and Secretary
- --
- Flavio Palumbo
- Chief Commercial Officer
- 217.60K
- Paul Brennan
- Chairman of the Board
- 132.17K
- Stephen Anastasiou
- Independent Director
- 70.00K
- Daniel Pollock
- Independent Director
- 104.98K
- Dr. Roger Aston
- Independent Director
- 116.03K
- Professor Ravi Savarirayan
- Independent Director
- 70.00K
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
%Chg